Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
暂无分享,去创建一个
Yan Liu | G. Gao | X. Fang | Z. Chen | Z. Hu | Zhong-yu Hu | Y. Li | H. Ren | Jian-feng Wang | C. Li | J. Wang | L. Liu | C. Wang | L. Dai | J. Li | S. Meng | Fangjun Li | S. Tian | P. He | Y. Liu | F. Li | X. Zhao | X. Yu | Y. Luo | C. Wu | E. Huang | L. Wu | Yi Luo | J. Yan | S. Yang | L. Gao | Shilong Yang | Siyu Tian | Fengze Wang | X. Duan | Z. Zhong | F. Wang | L. Wu | F. Li | Z. Hu | George F. Gao | Xiaomin Duan | Yan Li | Peng He | Changgui Li | Xin Fang | Chenfei Wang | Xiang Zhao | Changwei Wu | Zaixin Zhong | Lili Wu | Zhihai Chen | Junhua Li | Xian Yu | Hong-rui Ren | Lihong Liu | Shufang Meng | Jinghua Yan | Lidong Gao
[1] G. Gao,et al. Viral targets for vaccines against COVID-19 , 2020, Nature reviews. Immunology.
[2] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[3] Elisabeth Mahase. Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy , 2020, BMJ.
[4] Elisabeth Mahase. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week , 2020, BMJ.
[5] Nguyen H. Tran,et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.
[6] Shibo Jiang,et al. Learning from the past: development of safe and effective COVID-19 vaccines , 2020, Nature Reviews Microbiology.
[7] Wenling Wang,et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.
[8] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[9] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[10] R. Baric,et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.
[11] A. Gintsburg,et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.
[12] V. Shinde,et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.
[13] J. Bloom,et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate , 2020, Journal of Clinical Microbiology.
[14] J. Bloom,et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate , 2020, medRxiv.
[15] Yongli Yang,et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.
[16] E. Walsh,et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.
[17] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[18] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[19] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[20] G. Gao,et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS , 2020, Cell.
[21] John P. Moore,et al. SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds. , 2020, Journal of virology.
[22] A. Sette,et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.
[23] Rongchang Chen,et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment , 2020, Cell.
[24] G. Gao,et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.
[25] Y. Hu,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.
[26] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[27] Xiangxi Wang,et al. Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.
[28] Shibo Jiang,et al. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses , 2020, Frontiers in Microbiology.
[29] G. Gao,et al. Description of the First Strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain — National Pathogen Resource Center, China, 2020 , 2020, China CDC weekly.
[30] G. Gao,et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.
[31] G. Gao,et al. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond , 2015, Trends in Microbiology.